文献速递慢性肾脏病肾小球疾病遗传性与小管间质肾病

雷米普利在儿童Alport综合征中的肾脏保护治疗:多中心随机安慰剂对照双盲3期试验

A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome.
PubMed 文献 · Kidney Int · 2020-01-17

该多中心随机安慰剂对照双盲3期试验在14个德国中心纳入66例寡症状儿童Alport综合征患者,评估雷米普利治疗3-6年加6个月随访的安全性和有效性。雷米普利治疗未显示安全问题(不良事件率比1.00,95%CI 0.66-1.53),虽未达显著性,但随机组疾病进展风险降低近半(HR 0.51,95%CI 0.12-2.20),贝叶斯证据合成后HR为0.52(95%CI 0.19-1.39)。

要点

  • 雷米普利在儿童Alport综合征中未显示安全问题,不良事件率比1.00(95%CI 0.66-1.53)。
  • 雷米普利可能降低疾病进展风险近半,但随机组结果未达统计学显著性(HR 0.51,95%CI 0.12-2.20)。
  • 早期启动肾脏保护治疗安全,支持通过筛查(含基因检测)早期干预以延缓肾衰竭。

核心结论

  • 雷米普利早期治疗在儿童Alport综合征中安全,并谨慎显示可降低疾病进展风险近半但未达显著性。

研究设计与样本

  • 多中心、随机、安慰剂对照、双盲3期试验,在14个德国中心纳入66例寡症状儿童Alport综合征患者。
  • 22例随机分配至雷米普利或安慰剂组,治疗3-6年加6个月随访;44例进入开放标签对照,与前瞻性真实世界未治疗数据比较。

主要发现

  • 雷米普利治疗总暴露216.4患者年,不良事件率比1.00(95%CI 0.66-1.53),未显示安全问题。
  • 随机组中雷米普利使疾病进展风险降低近半(HR 0.51,95%CI 0.12-2.20),并减轻白蛋白尿进展斜率和肾小球滤过下降。
  • 开放标签调整分析中雷米普利似乎再次降低进展风险近半(HR 0.53,95%CI 0.22-1.29)。
  • 贝叶斯证据合成随机和开放标签数据后,HR估计为0.52(95%CI 0.19-1.39)。

临床怎么用

  • 对于儿童Alport综合征,可考虑早期启动雷米普利肾脏保护治疗,因安全性已显示。
  • 筛查儿童和年轻成人肾小球血尿时,可纳入Alport相关基因变异的基因检测以早期识别并干预。

局限性

  • 随机组样本量小(22例),疗效结果未达统计学显著性。
  • 开放标签对照非随机,与真实世界数据比较可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children with Alport syndrome develop renal failure early in life. Since the safety and efficacy of preemptive nephroprotective therapy are uncertain we conducted a randomized, placebo-controlled, double-blind trial in 14 German sites of pediatric patients with ramipril for three to six years plus six months follow-up to determine these parameters. Pretreated children and those whose parents refused randomization became an open-arm control, which were compared to prospective real-world data from untreated children. The co-primary endpoints were safety (adverse drug reactions) and efficacy (time to progression). Out of 66 oligosymptomatic children, 22 were randomized and 44 joined the open-arm comparison. Ramipril therapy showed no safety issues (total of 216.4 patient-years on ramipril; adverse event rate-ratio 1.00; 95% confidence interval 0.66-1.53). Although not significant, our results cautiously showed that ramipril therapy was effective: in the randomized arm, Ramipril decreased the risk of disease progression by almost half (hazard ratio 0.51 (0.12-2.20)), diminished the slope of albuminuria progression and the decline in glomerular filtration. In adjusted analysis, indications of efficacy were supported by prospective data from participants treated open label compared with untreated children, in whom ramipril again seemed to reduce progression by almost half (0.53 (0.22-1.29)). Incorporating these results into the randomized data by Bayesian evidence synthesis resulted in a more precise estimate of the hazard-ratio of 0.52 (0.19-1.39). Thus, our study shows the safety of early initiation of therapy and supports the hope to slow renal failure by many years, emphasizing the value of preemptive therapy. Hence, screening programs for glomerular hematuria in children and young adults could benefit from inclusion of genetic testing for Alport-related gene-variants.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Gross O, Tönshoff B, Weber LT, et al. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome. Kidney Int. 2020. PMID: 32299679. doi:10.1016/j.kint.2019.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。